245 related articles for article (PubMed ID: 38114660)
21. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
22. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
23. PARP inhibitor resistance in ovarian cancer: Underlying mechanisms and therapeutic approaches targeting the ATR/CHK1 pathway.
Biegała Ł; Gajek A; Marczak A; Rogalska A
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188633. PubMed ID: 34619333
[TBL] [Abstract][Full Text] [Related]
24. ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib.
Wilson Z; Odedra R; Wallez Y; Wijnhoven PWG; Hughes AM; Gerrard J; Jones GN; Bargh-Dawson H; Brown E; Young LA; O'Connor MJ; Lau A
Cancer Res; 2022 Mar; 82(6):1140-1152. PubMed ID: 35078817
[TBL] [Abstract][Full Text] [Related]
25. Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.
Shah PD; Wethington SL; Pagan C; Latif N; Tanyi J; Martin LP; Morgan M; Burger RA; Haggerty A; Zarrin H; Rodriguez D; Domchek S; Drapkin R; Shih IM; Smith SA; Dean E; Gaillard S; Armstrong D; Torigian DA; Hwang WT; Giuntoli R; Simpkins F
Gynecol Oncol; 2021 Nov; 163(2):246-253. PubMed ID: 34620496
[TBL] [Abstract][Full Text] [Related]
26. Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations).
Mahdi H; Hafez N; Doroshow D; Sohal D; Keedy V; Do KT; LoRusso P; Jürgensmeier J; Avedissian M; Sklar J; Glover C; Felicetti B; Dean E; Mortimer P; Shapiro GI; Eder JP
JCO Precis Oncol; 2021; 5():. PubMed ID: 34527850
[TBL] [Abstract][Full Text] [Related]
27. Ratio-Dependent Synergism of a Doxorubicin and Olaparib Combination in 2D and Spheroid Models of Ovarian Cancer.
Eetezadi S; Evans JC; Shen YT; De Souza R; Piquette-Miller M; Allen C
Mol Pharm; 2018 Feb; 15(2):472-485. PubMed ID: 29283581
[TBL] [Abstract][Full Text] [Related]
28. Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2.
Rytelewski M; Maleki Vareki S; Mangala LS; Romanow L; Jiang D; Pradeep S; Rodriguez-Aguayo C; Lopez-Berestein G; Figueredo R; Ferguson PJ; Vincent M; Sood AK; Koropatnick JD
Oncotarget; 2016 Apr; 7(15):20825-39. PubMed ID: 26959114
[TBL] [Abstract][Full Text] [Related]
29. An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer.
Xu J; Gao Y; Luan X; Li K; Wang J; Dai Y; Kang M; Lu C; Zhang M; Lu CX; Kang Y; Xu C
Cancer Chemother Pharmacol; 2022 May; 89(5):683-695. PubMed ID: 35419627
[TBL] [Abstract][Full Text] [Related]
30. Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.
Jette NR; Radhamani S; Arthur G; Ye R; Goutam S; Bolyos A; Petersen LF; Bose P; Bebb DG; Lees-Miller SP
Br J Cancer; 2019 Oct; 121(7):600-610. PubMed ID: 31481733
[TBL] [Abstract][Full Text] [Related]
31. Chk1 inhibition-induced BRCAness synergizes with olaparib in p53-deficient cancer cells.
Zhao Y; Zhou K; Xia X; Guo Y; Tao L
Cell Cycle; 2023 Jan; 22(2):200-212. PubMed ID: 35959961
[TBL] [Abstract][Full Text] [Related]
32. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
[TBL] [Abstract][Full Text] [Related]
33. Adenosine receptor A2b confers ovarian cancer survival and PARP inhibitor resistance through IL-6-STAT3 signalling.
Chi L; Huan L; Zhang C; Wang H; Lu J
J Cell Mol Med; 2023 Aug; 27(15):2150-2164. PubMed ID: 37278400
[TBL] [Abstract][Full Text] [Related]
34. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
Konstantinopoulos PA; Wilson AJ; Saskowski J; Wass E; Khabele D
Gynecol Oncol; 2014 Jun; 133(3):599-606. PubMed ID: 24631446
[TBL] [Abstract][Full Text] [Related]
35. Combinatorial Efficacy of Olaparib with Radiation and ATR Inhibitor Requires PARP1 Protein in Homologous Recombination-Proficient Pancreatic Cancer.
Parsels LA; Engelke CG; Parsels J; Flanagan SA; Zhang Q; Tanska D; Wahl DR; Canman CE; Lawrence TS; Morgan MA
Mol Cancer Ther; 2021 Feb; 20(2):263-273. PubMed ID: 33268569
[TBL] [Abstract][Full Text] [Related]
36. Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
Moustafa D; Elwahed MRA; Elsaid HH; Parvin JD
PLoS One; 2021; 16(1):e0235025. PubMed ID: 33412559
[TBL] [Abstract][Full Text] [Related]
37. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
[TBL] [Abstract][Full Text] [Related]
38. ATR Inhibition Induces CDK1-SPOP Signaling and Enhances Anti-PD-L1 Cytotoxicity in Prostate Cancer.
Tang Z; Pilié PG; Geng C; Manyam GC; Yang G; Park S; Wang D; Peng S; Wu C; Peng G; Yap TA; Corn PG; Broom BM; Thompson TC
Clin Cancer Res; 2021 Sep; 27(17):4898-4909. PubMed ID: 34168048
[TBL] [Abstract][Full Text] [Related]
39. Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway.
Bahar E; Kim JY; Kim DC; Kim HS; Yoon H
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920140
[TBL] [Abstract][Full Text] [Related]
40. Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer.
Gralewska P; Gajek A; Marczak A; Rogalska A
J Hematol Oncol; 2020 Apr; 13(1):39. PubMed ID: 32316968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
